Methylcobalamin (1500mcg) + Dosulepin (75mg)
Prothiaden M 75mg/1500mcg Tablet is used in the treatment of neuropathic pain.
1 Strip of 15 Tablet
Image shown is a representation and may slightly vary from the actual product. Every effort is made to maintain accuracy of all information displayed.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Prothiaden M 75mg/1500mcg Tablet may be taken with or without food, but it is better to take it at a fixed time.
Prothiaden M 75mg/1500mcg Tablet is a combination of two medicines: Dosulepin/dothiepin and methylcobalamin. Dosulepin / Dothiepin is a tricyclic antidepressant which increases the levels of chemical messengers (serotonin and noradrenaline) that stop the movement of pain signals in the brain. Methylcobalamin is a form of vitamin B which helps in the production of myelin, a substance that protects nerve fibres and rejuvenates damaged nerve cells. Together, they relieve neuropathic pain (pain from damaged nerves).
Related Warnings
Interaction with alcohol is unknown. Please consult your doctor.
Prothiaden M 75mg/1500mcg Tablet may be unsafe to use during pregnancy.
Animal studies have shown adverse effects on the foetus, however, there are limited human studies. The benefits from use in pregnant women may be acceptable despite the risk. Please consult your doctor.
Prothiaden M 75mg/1500mcg Tablet is probably unsafe to use during lactation. Limited human data suggest that the drug could represent a significant risk to the baby.
It is not known whether Prothiaden M 75mg/1500mcg Tablet alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
There is limited information available on the use of Prothiaden M 75mg/1500mcg Tablet in patients with kidney disease. Please consult your doctor.
There is limited information available on the use of Prothiaden M 75mg/1500mcg Tablet in patients with liver disease. Please consult your doctor.
